Application of a simple quantum chemical approach to ligand fragment scoring for *Trypanosoma brucei* pteridine reductase 1 inhibition

Wiktoria Jedwabny1 · Joanna Panecka-Hofman2,3 · Edyta Dyguda-Kazimierowicz1 · Rebecca C. Wade2,4,5 · W. Andrzej Sokalski1

Received: 28 September 2016 / Accepted: 16 June 2017 / Published online: 7 July 2017
© The Author(s) 2017. This article is an open access publication

Abstract There is a need for improved and generally applicable scoring functions for fragment-based approaches to ligand design. Here, we evaluate the performance of a computationally efficient model for inhibitory activity estimation, which is composed only of multipole electrostatic energy and dispersion energy terms that approximate long-range ab initio quantum mechanical interaction energies. We find that computed energies correlate well with inhibitory activity for a compound series with varying substituents targeting two subpockets of the binding site of *Trypanosoma brucei* pteridine reductase 1. For one subpocket, we find that the model is more predictive for inhibitory activity than the ab initio interaction energy calculated at the MP2 level. Furthermore, the model is found to outperform a commonly used empirical scoring method.

Finally, we show that the results for the two subpockets can be combined, which suggests that this simple nonempirical scoring function could be applied in fragment–based drug design.

Keywords Pteridine reductase 1 · PTR1 · Interaction energy · Ab initio · Nonempirical model · Binding affinity prediction

Introduction

Empirical computational methods are widely used in ligand discovery projects for ligand docking and computing ligand–receptor binding energetics. Docking procedures using empirical scoring functions are often found to successfully predict poses, but commonly lack sufficient accuracy to correctly rank poses or predict binding affinities [1–4]. On the other hand, rigorous ab initio quantum mechanical methods offer the possibility of more accurate calculations, but are generally too computationally costly and therefore impractical in drug design projects. Nevertheless, quantum chemical calculations may provide deeper insights into the physical nature of the corresponding interactions and lead to simpler and more robust nonempirical models. An example is the finding that for polar or charged inhibitors of phenylalanine ammonia-lyase and leucine aminopeptidase, the nonempirical first-order electrostatic interaction energy defined within perturbation theory [5] (or its multipole component [6]) alone yielded a reasonable correlation with experimental inhibitory activity data. However, such a simple model is insufficient for nonpolar receptors, like fatty acid amide hydrolase (FAAH), where inclusion of a nonempirical dispersion term, in addition to the electrostatic multipole

Wiktoria Jedwabny and Joanna Panecka-Hofman have contributed equally to the investigation.

Electronic supplementary material The online version of this article (doi:10.1007/s10822-017-0035-4) contains supplementary material, which is available to authorized users.

Edyta Dyguda-Kazimierowicz
Edyta.Dyguda@pwr.edu.pl

1 Department of Chemistry, Wrocław University of Science and Technology, Wrocław, Poland
2 Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), Heidelberg, Germany
3 Centre of New Technologies, University of Warsaw, Warsaw, Poland
4 Center for Molecular Biology (ZMBH), DKFZ-ZMBH Alliance, Heidelberg University, Heidelberg, Germany
5 Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Heidelberg, Germany
term, was necessary to describe inhibitory activities [7]. Likewise, as noted by Lonsdale et al. [8], dispersion effects should be considered for reliable modeling of enzyme-catalyzed reactions.

While the electrostatic multipole term estimated from atomic multipole moments obtained from RHF wavefunctions scales favorably with the number of atoms $A$ of the studied system as $O(A^2)$, the ab initio calculation of dispersion energy is much more computationally demanding, scaling as $O(N^3)$, where $N$ is the size of the basis set and, as such, it cannot be part of a generally applicable scoring method. A computationally inexpensive empirical expression for the dispersion energy employed by classical force fields [9] might be seen as a rational substitute for the ab initio calculations [10, 11]. However, empirical dispersion appears to be associated with a non-systematic error compared to rigorous DFT-SAPT results [10]. Another drawback of the classical term seems to arise for intermonomer distances shorter than equilibrium separation, wherein empirical results deviate from the reference DFT-SAPT calculations [11]. Since such shortened intermolecular distances might result from force field inadequacy [12] or basis set superposition error [13], any method including short range intermolecular energy terms sensitive to artificial compression of intermonomer separation is inadequate for the purpose of rapid estimation of the binding energy within protein–ligand complexes.

Most attempts to derive affordable and reliable dispersion corrections have been undertaken in conjunction with density functional theory methods, which do not account for the dispersive van der Waals forces unless special corrections are added [14–16]. Pernal et al. [17] proposed an alternative approach—a dispersion function $E_{\text{Das}}$ that describes noncovalent interactions by atom–atom potentials fitted to reproduce the results of high-level SAPT (Symmetry Adapted Perturbation Theory [18]) calculations that provide state-of-the-art quantum chemical dispersion and exchange-dispersion energies. It is noteworthy that the $E_{\text{Das}}$ function demonstrated remarkable performance in describing hydrogen bonding interactions, which are governed by both electrostatic and dispersive forces [19]. The low computational cost of this approximate dispersion function and its broad applicability stemming from the lack of empirical parametrization, make the use of the $E_{\text{Das}}$ expression a promising approach to describing dispersive contributions in scoring methods suited for virtual screening. Further advantages of the $E_{\text{Das}}$ term over van der Waals $1/r^6$ empirical expression discussed above are the clear physical meaning of the former and its pertinence to a wide range of intermolecular distances because of an additional higher order $1/r^8$ term and an exponential damping function that is essential at short distances where penetration effects become significant.

Here, we evaluate the ability of the simple model that was previously tested for a congeneric series of inhibitors of the FAAH protein [7], to predict the activities of inhibitors targeting two different subpockets of a protein binding site, which is an important requirement for application in fragment-based drug design approaches. In this model, the ligand–receptor interaction energy is approximated by the sum of the first-order electrostatic multipole component of the interaction energy, $E_{\text{ELMTP}}^{(1)}$ and $E_{\text{Das}}$, the aforementioned approximation of dispersion energy. The advantage of such a model is that it captures both long-range electrostatic and dispersive energy terms, while being relatively computationally efficient. The interaction energy of an inhibitor or a fragment of an inhibitor with the protein binding pocket is computed in a pairwise manner as the sum of amino-acid residue/inhibitor interaction energies for a set of residues defining the pocket or subpocket.

To validate the $E_{\text{ELMTP}}^{(1)} + E_{\text{Das}}$ approximation, here we compute several contributions to the second-order Møller–Plesset (MP2) interaction energy and assess their importance by evaluating correlation coefficients with experimentally determined inhibitory activities [20]. In these inhibitory activity models, we neglect the influence of binding free energy contributions such as entropy, desolvation energy and conformational adaptation of ligands and receptor upon binding. Our results suggest that this is a valid approximation when considering the relative binding free energies of a congeneric series of inhibitors that are expected to have similar binding modes. In addition, we examine various nonempirical representations of the dispersion term, to test the validity of the $E_{\text{Das}}$ approximation and the possibility of exchanging $E_{\text{Das}}$ with other dispersion corrections used with various DFT functionals. It should be noted that such corrections represent not only dispersion interactions but also other nonphysical deficiencies of DFT functionals [17].

In this study, we perform calculations for pteridine reductase 1 (PTR1), an enzyme involved in the pterin metabolism of trypanosomatid parasites [21, 22]. This enzyme, which is present in parasites but not humans, is a target for the design of inhibitors [20, 23–25] that disrupt the reduction of biopterin and folate in parasites and thus hinder their growth. In particular, PTR1 is an important enzyme in Trypanosoma brucei (Tb), which causes human African trypanosomiasis [26]. Different subpockets in the main binding site of TbPTR1 have been explored in inhibitor discovery projects and it therefore provides a good system for assessing the applicability of the simple nonempirical model for fragment–based approaches to inhibitor design.

In this work, we focus on the benzimidazol-2-amine series of potent, non-covalent, and reversible TbPTR1 inhibitors that was developed by Mpamhanga et al. [23]
and further extended by Spinks et al. [20], and for which apparent inhibitory activities ($K_{\text{app}}$; referred to in the following as ‘inhibitory activities’) against $Tb$PTR1 were measured. This series of compounds occupies the relatively hydrophobic $Tb$PTR1 subpockets adjacent to the binding site of the main enzyme substrate, biopterin (Fig. 1). Compound 11 from Ref. [20] (Fig. 1) is the parent compound for this inhibitor series [20, 23]. This compound adopts a well-defined binding mode in the crystal structure [23] (PDB code: 3GN2, see Fig. 1) stabilized by multiple hydrogen bonds, halogen bonds and stacking interactions. In particular, the N3 nitrogen of benzimidazole and the 2-amino group make hydrogen-bonds with the carboxylate group of the nearby Asp161 and the backbone carbonyl of Gly205 residue. On the other side of the binding pocket, the chlorines of the 3,4-dichlorophenyl moiety make halogen bonds with the backbone carbonyl group of Trp221 and the carboxylate group of the terminal Ala268 residue. The position of the scaffold of compound 11 is additionally stabilized by edge-face $\pi-\pi$ interactions (Fig. 1). Due to this extensive interaction pattern, we expect similar binding modes for the derivatives of compound 11. This assumption

Fig. 1 The crystal structure of $Tb$PTR1 in complex with compound 11 (PDB: 3GN2) showing the interactions made by the inhibitor in the binding site. (left) Interaction diagram of compound 11 with the $Tb$PTR1 protein pocket. A and D denote protein subunits in the $Tb$PTR1 homotetramer. (right) View of compound 11 (green with green semi-transparent surface contour) in the $Tb$PTR1 binding site, with residues within 3 Å of the ligand shown in stick representation and labeled. A fragment of the cofactor, nicotinamide adenine dinucleotide phosphate (NADP), is shown in yellow. The protein is rendered in cartoon representation. The substitution points (C4 and C7) in compound 11 are labeled. The edge-face $\pi-\pi$ interactions between the inhibitor and the protein are indicated by green dashed lines, while purple and yellow dashed lines denote hydrogen bonds and halogen bonds, respectively.

Fig. 2 Chemical structures of the C7 set of $Tb$PTR1 inhibitors [20]. The C7 position of the benzimidazole moiety is marked in yellow.
was used to model the TbPTR1–inhibitor complexes, for which crystallographic structures were not available.

To evaluate the $E_{ELMTP}^{(10)} + E_{Das}$ model for prediction of inhibitory activity, we first analyzed TbPTR1 derivatives of compound 11 substituted at C7 of the benzimidazole scaffold, i.e. the compounds reported in Fig. 2 (which we refer to as the C7 set). A similar analysis was previously performed for the docked covalent inhibitors of the FAAH enzyme [7]. The FAAH inhibitors were however modelled without knowledge of the crystallographically confirmed binding mode of the core scaffold, which probably introduced uncertainty into the results of the scoring model.

Here, our first aim was therefore to test the performance of the $E_{ELMTP}^{(10)} + E_{Das}$ model for another protein target, TbPTR1, with an inhibitor series with a well-defined binding mode. Our second aim was to investigate whether the model is general and additive, which is assumed since the interaction energy is calculated as a sum of the pairwise residue/inhibitor contributions. Thus, we made a similar model based on the model for the C7 set for the dataset of the C4–substituted compounds shown in Fig. 3 (which we refer to as the C4 set), with substituents interacting predominantly with a different set of residues than the C7 set. Our models for the C4 and C7 sets show transferability of the $E_{ELMTP}^{(10)} + E_{Das}$ model, suggesting its applicability to fragment-based drug design approaches.

### Methods

#### Preparation of the sets of compounds

Calculations were performed for (i) inhibitors from the C7 set [20] (Fig. 2) and (ii) inhibitors from the C4 set [20] (Fig. 3), which share a common parent scaffold: compound 11. The numbering of the inhibitors is adopted from Spinks et al. [20]. Of the reported inhibitors with substitutions at the C4 carbon of benzimidazole [20], two compounds, 26 and 27, were not included in the C4 set due to their weak inhibitory activities and because their binding modes presumably differ from that characterizing the remaining inhibitors (as suggested by our docking simulations). Further assumptions underlying our approach, i.e., the representation of the receptor and ligand structures with models of limited size, preclude consideration of inhibitors with entirely different binding poses. Compound 28 (Fig. 3) was reported to be contaminated with 25% of compound 33 (Fig. 2), and the inhibitory activity was measured for a mixture [20]. Thus, we calculated the inhibitory activity of the pure compound 28 based on the equilibrium equations for competitive binding. As reported in the Supplementary material, Section 1, the computed value was $K_{\text{app}}^i = 0.42 \mu M$.

#### Modeling of the protein–inhibitor complexes

The binding poses of the C7–set inhibitors were modelled in the TbPTR1 binding pocket based on the crystallographic binding mode of compound 11 (PDB code 3GN2 [23]). Following the recommended protein preparation protocol [27], crystallographic water molecules were removed and the resulting protein–inhibitor complexes were minimized in Maestro [28] using Protein Preparation Wizard [29] with the default OPLS 2005 [30] force field, and the convergence criterion defined as the non-hydrogen atom RMSD = 0.3 Å. Optimal hydrogen bonding was determined with PROPKA [31–34], implemented in Maestro, at pH 6.0, i.e. the pH used for the measurements of inhibitory activities [20].

The modelling procedure was similar for the C4– and C7–substituted compounds. However, for the C4 set, the modelling was more difficult because the TbPTR1 subpocket accommodating the C4 benzimidazole substituents is smaller and more enclosed than that for the C7 set. The binding pose of inhibitor 24 of the C4 set was modelled as described above, but we also analyzed the unminimized protein–inhibitor complex. For compounds 25 and 28, the conformations of the top score poses from QM-polarized docking (implemented in Maestro software suite [28]) were taken for the aforementioned minimization and structure preparation protocol. The QM-polarized
docking procedure consisted of the following steps: (i) Glide docking with XP (extra-precision) score [35, 36] and standard molecular mechanics OPLS 2005 force field electrostatic charges, (ii) recalculation of the semi-empirical Coulson's electrostatic point charges for the docked ligands in the protein surrounding, and (iii) redocking of the inhibitors with the electrostatic charges calculated in step (ii).

**Definition of the ligand fragments and TbPTR1 binding subpockets**

Since the binding mode of the common core of the inhibitors considered (i.e., compound 11) is well defined and likely to be positioned similarly for all inhibitors, its contribution to the observed binding affinity differences is most probably negligible. Therefore, to decrease the computational cost for the ab initio interaction energy calculations, the inhibitor structures were truncated to the fragments shown in Fig. 4 (named with a ‘fr-’ prefix). All the calculations refer to the inhibitor fragments shown in Fig. 4.

The TbPTR1 C7 binding subpocket consisted of residues from the first shell surrounding the C7 inhibitor fragments, see Fig. 5. Due to the potential flexibility of Cys168 and the limited ability of the restrained optimization protocol to account for more extensive conformational changes, Cys168 was excluded from the subpocket definition. Finally, the following residues were present in the C7 receptor model used for evaluating the interaction energy: Phe97, Phe171, Pro210, Met213, Glu217 and Trp221. Since Glu217 was hydrogen-bonded to Trp221, this residue was included in the calculations as a part of a Glu217–Trp221 dimer. The broken bonds arising from cutting the residues out of the protein scaffold were capped with hydrogen atoms optimized with Maestro using the protocol described above. The C4 system consisted of the following residues: Phe97, Asp161, Met163, Val164, Pro167, Cys168, Phe171, Tyr174, and Asn175, see Fig. 6. In this subsystem, in contrast to C7, Cys168 was included, because the rigid backbone of Cys is relatively close to the C4 substitution site, whereas the flexible side chain is not in direct contact (sulphur atom of Cys168 is located about 4.05 Å from carbon C4). Furthermore, in the main set of results, Asp161 was treated as protonated and the protonation of Asp161 at acidic pH is consistent with the catalytic mechanism of PTR1, as suggested by Gourley et al. [37]. Notably, the systems with protonated Asp161 display significantly better correlation of the energy contributions with the $pK_a^{app}$ values than those with unprotonated Asp161.

![Fig. 4](image_url) **Fig. 4** Fragments of the TbPTR1 inhibitors defined for calculations. Carbon atoms corresponding to the C7 and C4 positions of benzimidazole in the full inhibitor structures are marked in yellow and orange, respectively

![Fig. 5](image_url) **Fig. 5** The C7 subpocket and ligand fragments. Superimposed structures of the complexes of TbPTR1 with the C7 inhibitor fragments showing the surrounding residues included in the calculations. The hydrogen bond between Glu217 and Trp221 is shown by a green dashed line.
the interaction energy terms discussed herein). $E_{\text{ELPEN}}^{(10)}$ is the electrostatic penetration energy, calculated from the following expression: $E_{\text{ELPEN}}^{(10)} = E_{EL}^{(10)} - E_{\text{EL,MTP}}^{(10)}$, where $E_{EL}$ represents the first-order electrostatic energy. The first-order exchange energy $E_{\text{EX}}^{(10)}$ term in Eq. 1 is calculated from the first-order Heitler–London energy, $E_{\text{EX}}^{(10)}$: $E_{\text{EX}}^{(10)} = E_{\text{SCF}}^{(10)} - E_{\text{EL}}^{(10)}$. The higher-order delocalization energy, $E_{\text{DEL}}^{(R0)}$, is calculated as: $E_{\text{DEL}}^{(R0)} = E_{\text{SCF}}^{(10)} - E_{\text{EL}}^{(10)}$, where $E_{\text{SCF}}$ is the counterpoise-corrected self-consistent field variational energy. The correlation term is defined as: $E_{\text{CORR}}^{(2)} = E_{MP2} - E_{\text{SCF}}$. The $E_{\text{EL,MTP}}$ and $E_{\text{CORR}}^{(2)}$ contributions are considered long-range energy terms, i.e. they vary with the intermolecular distance $R$ as $R^{-n}$ ($n \in \mathbb{N}$), whereas $E_{\text{EL,PEN}}^{(10)}$, $E_{\text{EX}}^{(10)}$ and $E_{\text{DEL}}^{(R0)}$ are short-range terms, i.e. they vary as $\exp^{-\gamma R}$ with $R, \gamma > 0$ (see Eq. 1).

Ab initio interaction energy calculations

The interaction energy between each residue (a single residue monomer or the Glu217–Trp221/Met163–Val164 dimers) and each inhibitor fragment was calculated with a modified version [39] of the GAMESS program [41] using the 6-311G(d) [42, 43] basis set with diffuse functions on the s and p orbitals of the chlorine atoms [44, 45]. This approach was chosen rather than using a full 6-311++G(2d,2p) basis set to save computational time and because we did not notice major qualitative differences in the results (a comparison is given in the Supplementary material, Table S1). A counterpoise correction was applied to avoid basis set superposition error [46].

Multipole electrostatic energy terms were calculated using the Cumulative Atomic Multipole Moments (CAMM) approach [40, 47] implemented in GAMESS with the expansion truncated at the $R^{-3}$ term. Exponential truncation of the CAMM expansion at the $(1/R)^n$ term seems to limit the disruptive effect of diffuse functions on higher rank multipoles and yields the best results for $n = 3$, i.e. including the atomic dipole–dipole and monopole–quadrupole terms.

In addition, three dispersion energy models were tested and compared as regards their suitability for this application, namely: (i) as a reference, the $E_{\text{CORR}}^{(2)}$ term from the HVPT energy decomposition scheme, (ii) the $E_{\text{DAS}}$ function [17, 19] fitted to the SAPT [18] results, and (iii) the D3 correction [48] to dispersionless—DFT with Becke–Johnson damping [49] applied. The latter was calculated with standalone DFT-D3 program (version 3.1. Rev 1) [48, 49], using three different functionals, namely the hybrid functionals PBE0 [50, 51] and B3LYP [52], and the exchange functional TPSS [53]. D3 is defined as a dispersion correction being the sum of two- and three-body contributions to the dispersion energy [48].
Data analysis

Each scoring model considered was compared with the experimental inhibitory activities ($pK_{\text{app}}^i$) by computing Pearson correlation coefficients (R) and the success rate of prediction of relative binding affinities ($N_{\text{pred}}$). The latter is defined as the percentage of concordant inhibitor pairs with relative stability of the same sign as in the reference experimentally measured activities, evaluated among all pairs of the inhibitor set (C4 or C7) [54]. Note that when Pearson correlation coefficients between the calculated interaction energies in our model and the experimental inhibitory activities are negative (trends of the aforementioned data sets are opposite), these values are said to correlate, as lower values of energy should ideally accompany increasing inhibitory activity. For the inverse relationship associated with a positive Pearson correlation coefficient, we use the term “anticorrelation”. The XP (extra-precision) scoring in the Glide program [35, 36, 55], with the “score-in-place” option, was applied for empirical scoring of the fragments used for the ab initio calculations. The score function is expressed as follows:

$$\text{XP GlideScore} = E_{\text{coul}} + E_{\text{vdW}} + E_{\text{bind}} + E_{\text{penalty}}$$

(2)

$E_{\text{coul}}$ and $E_{\text{vdW}}$ are electrostatic and van der Waals terms, respectively, $E_{\text{penalty}}$ includes a desolvation penalty and a ligand strain energy which are unfavorable for binding, while $E_{\text{bind}}$ is composed of favourable terms similar to those in the ChemScore function [56]. The $E_{\text{bind}}$ terms of the XP GlideScore additionally include: (i) a model of hydrophobic interactions, which takes into account ligand hydrophobic enclosure, and (ii) an improved model of hydrogen bond interactions [36]. The above scoring function was tested on 198 protein–ligand complexes, resulting in binding free energy RMSDs of 2.26 and 1.73 kcal mol$^{-1}$ over all and selected well-docked ligands, respectively, as reported by Friesner et al. [36].

Results and discussion

The $E_{\text{EL}}^{(10)}$ and $E_{\text{MTP}}$ interaction energies correlate with $pK_{\text{app}}^i$ values of the C7 set

The total interaction energy values calculated at the consecutive levels of theory are shown in Table 1. Moreover, the relationship between these interaction energies and exchange, delocalization and correlation contributions is depicted in Fig. S1 in the Supplementary Material. The corresponding pairwise interaction energy values for inhibitor–residue pairs and the numerical values of exchange and delocalization energy components are presented in the Supplementary material (Tables S2, S3, respectively).

Table 1 shows that the $E_{\text{MTP}}$ interaction energy significantly correlates with the experimentally determined inhibitory activities ($R = -0.89$). Apart from fr-29, the $E_{\text{MTP}}$ values reflect the ranking of the inhibitors established experimentally. Furthermore, the $E_{\text{EL}}^{(10)}$ values correlate with the experimental data ($R = -0.84$), but with a lower $N_{\text{pred}}$ value than for $E_{\text{MTP}}$ (80 vs. 86.7%, respectively).

For the fragments of three least potent inhibitors of the C7 set, fr-29, fr-33, and fr-11, the differences in $pK_{\text{app}}^i$ of about 0.1 (corresponding to an approximately 0.1 kcal mol$^{-1}$ difference in binding free energy [57]), cannot be expected to be reproduced computationally, as they exceed the accuracy of most quantum chemical calculations, and, likely, of the experiments (measurement errors are, however, not explicitly provided in Refs. [20, 23]). Accordingly,

| Inhibitor | $pK_{\text{app}}^i$ | $E_{\text{EL MTP}}^{(10)}$ | $E_{\text{EL}}^{(10)}$ | $E_{\text{EL}}^{(10)}$ | $E_{\text{SCF}}$ | $E_{\text{MTP}}$ | $E_{\text{EL MTP}}^{(10)} + E_{\text{Di}}$ | $E_{\text{EL}}^{(10)} + E_{\text{CORR}}$ |
|-----------|-----------------|------------------|-----------------|-----------------|----------------|----------------|----------------|----------------|
| fr-32     | 8.2             | -4.4             | -8.3            | 10.8            | 7.0            | -9.5           | -25.8          | -20.9         |
| fr-30     | 7.3             | -3.4             | -6.9            | 7.6             | 4.5            | -8.8           | -21.9          | -16.7         |
| fr-31     | 7.0             | -0.2             | -7.0            | 12.2            | 8.9            | -7.9           | -20.2          | -16.9         |
| fr-29     | 6.3             | -1.3             | -3.0            | 6.2             | 4.6            | -4.0           | -12.2          | -9.8          |
| fr-33     | 6.2             | -3.0             | -5.9            | 5.3             | 3.3            | -6.4           | -15.5          | -12.7         |
| fr-11     | 6.1             | -2.5             | -4.6            | 5.1             | 3.6            | -4.1           | -12.4          | -10.1         |
| R$^b$     | -0.48           | -0.84            | 0.76            | 0.62            | -0.89          | -0.96          | -0.95          |
| $N_{\text{pred}}$ | 66.7           | 80.0             | 13.3            | 26.7            | 86.7           | 86.7           | 80.0           |

In units of kcal mol$^{-1}$

$^a$Experimental $pK_{\text{app}}^i$ values are taken from Ref. [20]

$^b$Pearson correlation coefficient between the calculated energy and the experimental inhibitory activity

$^c$Percentage of concordant pairs (%)
the computed binding energies of fr-29, fr-33, and fr-11 ligands would be expected to be similar. It can be seen in Table 1 that fr-29 and fr-11, but not fr-33, have similar $E_{MP2}$ interaction energy values. Actually, the $E_{MP2}$ binding energies of the C7 set inhibitors with an oxygen atom at the C7 position (i.e., compounds 30, 31, and 33) appear to be slightly overestimated (see Fig. S2 in the Supplementary material) whereas, the inhibitors with a hydrophobic C7 substituent have underestimated values of $E_{MP2}$ interaction energy. Notably, the C7 substituents are in direct contact with the methylene linker of the common scaffold depicted in Fig. 2 (e.g., the distance between the C7 chlorine and the closest hydrogen atom of the adjacent methyl group in compound 29 is 2.7 Å). Considering that this particular part of the inhibitor was not included in binding energy analysis, the observed under- and overestimation of interaction energy could be associated with intramolecular interactions that are not accounted for by the model. Despite these omissions, the overall correlation with experimental inhibitory activity is satisfactory.

On the other hand, both $E^{(10)}$ and $E_{SCF}$ anti-correlate with inhibitory activities, i.e., these energies tend to indicate greater repulsion for the compounds with higher inhibitory activity. Positive values of the $E^{(10)}$ and $E_{SCF}$ energies result from the repulsive exchange contribution, $E^{(10)}_{EX}$ (Table S3 in the Supplementary material). The repulsion is stronger for more potent inhibitors, since the molecular fragments that interact strongly are also more likely to experience stronger exchange effects [54, 58]. For example, for fr-31, the $E^{(10)}$ and $E_{SCF}$ interaction energy terms appear to be exceptionally high (i.e., unfavorable) due to the incorporation of short-range exchange contribution. The short-range effects are exponentially dependent on the interatomic distance, so any minor structural defect (e.g., artificial shortening of the intermolecular distance due to the basis set superposition error or the difference between the crystal structure and the gas phase or the force field non-transferability) results in significant errors in the energy values. Therefore, $E^{(10)}$ and $E_{SCF}$ are vulnerable to structural deficiencies in the model [7, 58], and are not really applicable for studying crystal structure-based models of the protein–ligand complexes.

Although the delocalization term, $E^{(RO)}_{DEL}$ accounted for at the Hartree–Fock level of theory is characterized by a correlation coefficient $R = −0.94$ (see the Supplementary material, Table S3), it is still insufficient to overcome the inverse inhibitory ranking due to the $E^{(10)}_{EX}$ contribution (Fig. S1 in the Supplementary material). Only the $E^{(2)}_{CORR}$ contribution to the $E_{MP2}$ energy restores the proper ranking of the inhibitory activities (Table 1). As demonstrated in Fig. S1 in the Supplementary material, both the $E^{(RO)}_{DEL}$ and $E^{(2)}_{CORR}$ terms approximately cancel out the repulsive characteristics of the exchange component, but $E^{(2)}_{CORR}$ is the major contribution out of these two.

The above analysis is in line with our previous findings for FAAH inhibitors [7] that omitting the contributions arising from short-range interactions (i.e., considering only the multipole electrostatic and correlation energy components) results in a much better model for predicting the inhibitory activity [7].

The $E_{Das}$ approximation predicts inhibitory activities of the C7–set inhibitors as well as the correlation energy

The results shown in Table 2 indicate that, for the C7–set inhibitors, the dominant dispersion contribution could even serve as a standalone scoring method, with $R = −0.86$ for $E^{(2)}_{CORR}$. Furthermore, for the C7 inhibitor set, the $E_{Das}$

### Table 2 $E_{Das}$ function and the D3 dispersion energy approximations evaluated for the C7–set inhibitor fragments

| Inhibitor | $pK_{a}^{exp}$ | $E^{(10)}_{CORR}$ | $E_{Das}$ | $D3_{B3LYP}$ | $D3_{TPSS}$ |
|-----------|----------------|-----------------|-----------|--------------|-------------|
| fr-32     | 8.2            | −16.5           | −12.3     | −17.6        | −15.7       |
| fr-30     | 7.3            | −13.3           | −10.9     | −15.5        | −13.8       |
| fr-31     | 7.0            | −16.8           | −12.2     | −17.1        | −15.4       |
| fr-29     | 6.3            | −8.5            | −6.5      | −9.2         | −8.2        |
| fr-33     | 6.2            | −9.7            | −7.5      | −10.5        | −9.4        |
| fr-11     | 6.1            | −7.6            | −5.7      | −8.2         | −7.3        |

In units of kcal mol$^{-1}$

*Experimental affinity values are taken from Ref. [20]

**Pearson correlation coefficient between the dispersion approximation and the correlation energy $E^{(2)}_{CORR}$

*% Pearson correlation coefficient between the calculated dispersion approximation and the experimental inhibitory activity taken from Ref. [20]

%Percentage of concordant pairs (%)
approximation correlates with the inhibitory activities as well as $E_{\text{CORR}}^{(2)}$ ($R = -0.92$), thereby confirming the validity of the $E_{\text{Das}}$ approximation. A significant correlation is obtained for the $E_{\text{CORR}}^{(2)}$ and $E_{\text{Das}}$ energies because the $C7$–set of inhibitor fragments consists of largely hydrophobic substituents targeting a relatively hydrophobic $Tb$PTR1 subpocket, and thus dispersive interactions play a major role in binding.

Nonetheless, a universal scoring model should also account for the electrostatic contribution, so that it is appropriate for noncovalent complexes with intermolecular forces of either dispersive or electrostatic nature (or a mixture of both). Upon including the electrostatic multipole term, the scoring abilities of the proposed model further improve for the $C7$ inhibitor set (Table 1): for $E_{\text{ELMTP}}^{(10)} + E_{\text{Das}}$ and $E_{\text{ELMTP}}^{(10)} + E_{\text{CORR}}$ models the correlation coefficients are equal to $-0.96$ and $-0.95$, respectively. Furthermore, the $E_{\text{ELMTP}}^{(10)} + E_{\text{Das}}$ model correctly predicted 86.7% of concordant pairs, i.e. as many as for the $E_{\text{MP2}}$ level. Note that for the $E_{\text{ELMTP}}^{(10)} + E_{\text{Das}}$ model describing $Tb$PTR1 inhibition, the correlation is distinctly better than for the inhibitors of the FAAH enzyme ($R = -0.67$) [7]. This difference might be due to the higher flexibility of the FAAH inhibitor series, which may cause problems in determining the correct binding pose even by the most accurate docking procedures.

Comparison of dispersion models: alternatives to the $E_{\text{Das}}$ function

In the work presented herein, we additionally tested the D3 correction to dispersionless—DFT developed by Grimme et al. [48], calculated for the following functionals: PBE0, B3LYP, and TPSS. Our objective was to check how the simple $E_{\text{Das}}$ approximation is related to the widely tested D3 correction. The performance of the dispersion approximations for the $C7$ set is compared in Table 2.

All the dispersion approximations correlate well with the $E_{\text{CORR}}^{(2)}$ results. Considering the agreement with the experimental inhibitory activities, the dispersion energies calculated from the D3 corrections perform comparably well with the other methods, with a correlation coefficient $R$ of about $-0.90$ for all the three tested functionals, whereas for $E_{\text{Das}}$ and $E_{\text{CORR}}^{(2)}$ the values of $R$ are equal to $-0.92$ and $-0.86$, respectively. While each dispersion approximation considered here performs remarkably well, the dispersion model proposed by Pernal et al. [17] is fitted to the SAPT results, whereas the results obtained with D3 corrections might, in general, depend on the applied functional. Accordingly, the choice of certain functional might not be obvious if structure–activity relationships are to be predicted for novel receptor–ligand complexes not characterized experimentally, wherein prior testing of the performance of a given method cannot be carried out.

Comparison of the $E_{\text{ELMTP}}^{(10)} + E_{\text{Das}}$ model with empirical scoring

Protein–ligand interactions are routinely evaluated with computationally inexpensive empirical scoring approaches [59]. These rely on empirical parameters that are typically derived using a diverse training set. Although, in principle, generally applicable, such scoring functions have been shown to perform successfully in some applications and to fail in others [1, 60]. In Fig. 7, the nonempirical $E_{\text{ELMTP}}^{(10)} + E_{\text{Das}}$ scoring method is compared with the Glide XP scoring function [35]; the corresponding values are given in the Supplementary material (Table S4). Notably, the predictive capabilities of the $E_{\text{ELMTP}}^{(10)} + E_{\text{Das}}$ model, tested on the $C7$ set of inhibitor fragments, outperform the empirical scoring function, with an $R$ correlation coefficient of $-0.96$ compared to $-0.82$ value obtained with Glide XP.

An important advantage of the $E_{\text{ELMTP}}^{(10)} + E_{\text{Das}}$ model is that it is fully based on well-defined long-range interaction energy components obtained from first principles ab initio calculations and does not contain any empirical parameters. Moreover, the method is as computationally affordable as commonly used empirical scoring functions, scaling as $O(A^2)$ [7]. Overall, these results suggest that more accurate, nonempirical ways of assessing the protein–ligand interactions might be advantageous for the design of novel inhibitors, and that a gain in the quality of the results can be achieved with little computational effort.
Sensitivity of the $E_{\text{EL,MTP}}^{(10)} + E_{\text{Das}}$ and $E_{\text{MP2}}$ models to the inhibitor–receptor modelling procedure—the case of compound 24 in the C4 set of inhibitors

We performed calculations for the C4 set of inhibitor fragments, targeting another subpocket of TbPTR1. Table 3 shows the interaction energies calculated at the different levels of theory, together with the $E_{\text{EL,MTP}}^{(10)} + E_{\text{CORR}}^{(2)}$ and $E_{\text{EL,MTP}}^{(10)} + E_{\text{Das}}$ models. The corresponding interaction energy values for each residue–inhibitor fragment pair are presented in the Supplementary Material (Table S6).

Since modeling of the C4 set of inhibitor–protein complexes was not as straightforward as for the C7 set, we analyzed the influence of the modeling procedure, in particular the classical force field minimization of the TbPTR1–inhibitor complex, on the computed energy values for one inhibitor, compound 24. In this case, we suspected that the classical force field description [30], which models atoms as spheres with point charges, might incorrectly treat the interactions of 4-Cl substituent with the side chain of Asn175. Due to the complex electronic structure of halogens and the resultant o-halo phenomenon, the chlorine may form the so-called halogen bond, which is poorly described in commonly-used force fields [61].

We observed that classical minimization distinctly changes coordinates of this system, with the distance between 4-Cl of compound 24 and amide N of Asn175 decreasing from 5.0 to 3.9 Å (see Fig. S3 in the Supplementary material). For the minimized compound 24 complex, the exchange energy $E_{\text{EX}}^{(10)}$ is much lower than for the unminimized complex (29.2 vs. 44.7 kcal mol$^{-1}$, see Table S7 in the Supplementary material). This difference suggests that minimization reduces some steric clashes in the complex. Furthermore, with minimized compound 24, $E_{\text{EX}}^{(10)}$ anti-correlates with $pK_{\text{app}}^{\text{i}}$ for the four C4 compounds, whereas with the unminimized compound 24 complex, no such anti-correlation is observed ($R = 0.69$ vs. $-0.03$, respectively, Table S7). This is likely the reason why $E_{\text{MP2}}$ does not correlate with $pK_{\text{app}}^{\text{i}}$ for the C4 set with minimized inhibitor 24 ($R = 0.21$, Table 3), whereas it correlates for the unminimized compound 24 ($R = -0.85$). On the other hand, the $E_{\text{EL,MTP}}^{(10)} + E_{\text{Das}}$ model (which does not include $E_{\text{EX}}^{(10)}$) shows the expected inverse relation with $pK_{\text{app}}^{\text{i}}$ for both the minimized ($R = -0.59$) and the unminimized ($R = -0.35$) inhibitor 24 (Table 3). Thus, the results suggest that the $E_{\text{EL,MTP}}^{(10)} + E_{\text{Das}}$ model is more robust than the $E_{\text{MP2}}$-based model to inaccuracies in the models of the inhibitor–receptor complexes.

**Limitations of the $E_{\text{EL,MTP}}^{(10)} + E_{\text{Das}}$ model due to omission of the exchange energy**

For the C4 set, the correlation of $E_{\text{EL,MTP}}^{(10)} + E_{\text{Das}}$ with $pK_{\text{app}}^{\text{i}}$ is not as good as for the C7 set (compare Tables 1, 3). This is likely due to the lower number of inhibitors and the narrow range of $pK_{\text{app}}^{\text{i}}$ values in this set. However, if we investigate how well the $E_{\text{EL,MTP}}^{(10)} + E_{\text{Das}}$ model approximates the reference $E_{\text{MP2}}$ energy, omitting compound 25 significantly increases the correlation between $E_{\text{MP2}}$ and $E_{\text{EL,MTP}}^{(10)} + E_{\text{Das}}$, which is 0.27 for all inhibitors and 0.93 when compound 25 is excluded from the C4 set (see Table S8 in the Supplementary material). Notably, $E_{\text{EX}}^{(10)}$ of compound 25 seems to be overestimated (unfavourable for binding), while $E_{\text{CORR}}^{(2)}$ (and $E_{\text{Das}}$) are too favourable (see Table S7 in the

| Inhibitor | $pK_{\text{app}}^{\text{i}}$ | $E_{\text{EL,MTP}}^{(10)}$ | $E_{\text{EL}}^{(10)}$ | $E_{\text{SCF}}$ | $E_{\text{MP2}}$ | $E_{\text{EL,MTP}}^{(10)} + E_{\text{Das}}$ | $E_{\text{EL,MTP}}^{(10)} + E_{\text{CORR}}^{(2)}$ |
|-----------|------------------|------------------|------------------|----------------|----------------|-------------------------------|-------------------------------|
| fr-25     | 6.5              | -1.7             | -16.9            | 32.9           | 24.6           | -4.4                          | -48.8                         |
| fr-28     | 6.4              | -0.1             | -11.7            | 21.4           | 16.0           | -5.8                          | -33.4                         |
| fr-11     | 6.1              | 1.0              | -9.5             | 19.5           | 14.8           | -2.4                          | -22.7                         |
| fr-24     | 5.6              | -0.2             | -10.4            | 18.7           | 13.9           | -6.0                          | -29.8                         |
| R$^b$     | -0.44            | -0.66            | 0.70             | 0.71           | 0.21           | -0.59                         | -0.59                         |
| N$^{\text{pred}}$ | 66.7            | 83.3             | 0.0              | 0.0            | 33.3           | 83.3                          | 83.3                          |
| fr-24$^*$ | 5.6              | -2.1             | -17.7            | 27.1           | 19.9           | -1.7                          | -36.0                         |
| R$^b$     | 0.27             | 0.28             | 0.14             | 0.17           | -0.85          | -0.35                         | -0.33                         |
| N$^{\text{pred}}$ | 50.0            | 50.0             | 33.3             | 33.3           | 83.3           | 66.7                          | 66.7                          |

*In units of kcal mol$^{-1}$

The data for the unminimized compound 24 complex are marked by *

*aExperimental affinity values are taken from Ref. [20]

bPearson correlation coefficient between the calculated energy and the experimental inhibitory activity

cPercentage of concordant pairs (%)
Supplementary material). For this compound, even the standard docking procedure shows that the side chain makes steric clashes, and these contacts could not be properly relaxed by energy minimization procedure (see Fig. S4 in the Supplementary Material). The omission of the $E_{IX}^{(10)}$ energy, and thereby the effects of short-range repulsion, in the $E_{EL,MTP}^{(10)} + E_{Das}$ model mean that it should not be applied when there are significant ligand–receptor clashes, such as observed for compound 25. This problem can be detected at the early stage of modeling/docking prior to the QM calculations. Since the $E_{EL,MTP}^{(10)} + E_{Das}$ model does not properly capture the interactions of inhibitor 25, we omitted this compound in further analysis.

Putting the $C7$ and $C4$ models together

Analysis of correlations for the $C4$-set models should be treated with caution since the dataset (excluding inhibitor 25) consists of only three inhibitors with a very narrow $pK_{i}^{app}$ range. Therefore, we did not make correlation models for these points alone. Instead, we fitted these data points to the $C7$–set $E_{EL,MTP}^{(10)} + E_{Das}$ and $E_{MP2}$ models, assuming per-residue additivity of the models (see explanation in the Supplementary material), which requires that $\alpha$ parameter in the $E = \alpha \cdot pK_{i}^{app} + \beta$ models for the $C7$ system was kept constant and the $\beta$ parameter was fit by minimizing the deviation of the three $C4$ experimental $pK_{i}^{app}$ values. The use of different $\beta$ values for different subpockets reflects the fact that there is a different energetic contribution to binding for each substituent position but that this contribution can be assumed constant for all compounds with substituents at a given position. Fig. 8 shows the fitted $E_{MP2}$ and $E_{EL,MTP}^{(10)} + E_{Das}$ models for the $C7$ and the $C4$ set. It can be seen in Fig. 8 that, for both inhibitor sets, predictions of the regression models are generally worse for the weaker binders, which form less specific and less stable interactions, and are thus more challenging to model.

The $E_{MP2}$ models for the $C7$ set and the $C4$ or $C4^*$ set (for unminimized inhibitor 24) are remarkably consistent (see Fig. 8a; Table 4). This is confirmed by low RMS errors in $pK_{i}^{app}$ values (0.8 and 0.4 for the $C4$ and $C4^*$ sets, respectively; Table 4). Thus, the $E_{MP2}$ model seems to be transferable between the $C4$ and $C7$ pockets. The $E_{EL,MTP}^{(10)} + E_{Das}$ energy performs overall worse in predicting $pK_{i}^{app}$ values than $E_{MP2}$ (Table 4), although it also shows reasonable transferability of the $C7$ model to the $C4$ subpocket (Fig. 8b; Table 4). The subpockets feature differing physico-chemical properties ($C7$—more hydrophobic, $C4$—more hydrophilic; compare Figs. 2, 3), but similar hydrophobic character of the substituents may facilitate the

![Image](309x382 to 541x733)

**Table 4** Inhibitory activities $pK_{i}^{app}$ for the $C4$ set predicted with the best fitting equations obtained from the $E_{EL,MTP}^{(10)} + E_{Das}$ and $E_{MP2}$ models

| Inh. | Exp. | $E_{EL,MTP}^{(10)} + E_{Das}$ | $E_{MP2}$ |
|------|------|-----------------|----------|
|      |      | $E_{C4}$ | $E_{C4^*}$ | $E_{C4}$ | $E_{C4^*}$ |
| fr-28 | 6.4 | 6.8 | 6.4 | 6.5 | 7.0 |
| fr-11 | 6.1 | 5.1 | 4.8 | 5.1 | 5.7 |
| fr-24 | 5.6 | 6.2 | 6.9 | 6.5 | 5.4 |
| RMSE* | 0.7 | 1.0 | 0.8 | 0.4 |

The model has the same gradient $\alpha$ as the corresponding $C7$ model ($E = \alpha \cdot pK_{i}^{app} + \beta$).

The data sets with the unminimized compound 24 complex are marked by *.

See model parameters in Table S9 in the Supplementary material.

*Experimental $pK_{i}^{app}$ values are taken from Ref. [20].

**Table 4** Inhibitory activities $pK_{i}^{app}$ for the $C4$ set predicted with the best fitting equations obtained from the $E_{EL,MTP}^{(10)} + E_{Das}$ and $E_{MP2}$ models

(a)

![Image](309x382 to 541x733)

(b)

**Fig. 8** The $E_{MP2}$ (a) and $E_{EL,MTP}^{(10)} + E_{Das}$ (b) interaction energies versus experimental inhibitory activities and linear regression models for the $C4$ and $C7$ inhibitor sets. The same $\alpha$ value is used for the $C7$ and $C4$ models. Parameters of the models are presented in Table S9 in the Supplementary Material and $pK_{i}^{app}$ prediction results are given in Table 4. The data for the unminimized compound 24 (fr-24*) are also shown (in orange).
transferability of the models between subpockets, which should be further tested for ligands with more diverse properties.

Concluding remarks

We have conducted ab initio calculations of the interaction energies between a series of inhibitor fragments and binding subpockets of the TbPTR1 enzyme. The common scaffold for this inhibitor series was a derivative of benzimidazol-2-amine (compound 11), with a well-defined binding mode in TbPTR1. Two types of substitutions were analysed, i.e. substituents at the C7 carbon of benzimidazole scaffold (6 inhibitors, C7 set) and at the C4 position (4 inhibitors, C4 set), the two substituent sets interacting predominantly with different subpockets of the TbPTR1 protein.

For evaluation of the inhibitor–receptor interaction energies, we used the recently developed $E_{ELMT}^{{(10)}} + E_{Das}^{{(10)}}$ approximate model, including only multipole electrostatic and dispersive energy terms [7]. Combining these two terms is reasonable as they both are major long-range contributions to the intermolecular interaction energy. It is noteworthy that, despite the approximate approach, the model does not contain empirical parameters, i.e. it is parametrized only based on the theoretical SAPT results. The model, however, also involves the following approximations: (i) a reduced binding pocket representation that includes only the residues directly interacting with the inhibitors, and (ii) inhibitor–receptor interaction energy terms calculated in a pairwise manner, summing over contributions of each binding pocket residue. This calculation scheme, despite its simplicity, resulted in a good correlation with experimental inhibitory activities for both the C7 and the C4 sets of the TbPTR1 inhibitors. Furthermore, this computationally efficient model was more accurate in predicting inhibitory activities of TbPTR1 inhibitors than the extra-precision (XP) docking score of Glide (Schrödinger, Inc.). We also found that the replacement of the $E_{Das}$ function by the D3 correction to dispersionless—DFT could also be considered, since this approximation reflects the correlation energy contribution as accurately as the $E_{Das}$ energy. Unlike the latter, however, the D3 correction might be dependent on the choice of the functional and further validation is required to assess its range of applicability. Considering both the C7 and C4 sets of inhibitors, we obtained correlations with the experimental data for the $E_{ELMT}^{{(10)}} + E_{Das}^{{(10)}}$ model. For the more closed, confined C4 subpocket, the $E_{ELMT}^{{(10)}} + E_{Das}^{{(10)}}$ model performed less well but gave results comparable to those obtained for FAAH inhibitors [7]: $R = -0.59$ versus $-0.67$, respectively. The lower correlation for the C4 inhibitor set may be due to the low number of compounds with a narrow range of experimental $pK_{app}$ values. We found that $E_{ELMT}^{{(10)}} + E_{Das}^{{(10)}}$ is better able to overcome deficiencies of the model of the ligand–receptor complex for the halogenated compound (inhibitor 24) than the interaction energy at the MP2 level of theory. However, the applicability of the $E_{ELMT}^{{(10)}} + E_{Das}^{{(10)}}$ model is limited by the omission of the $E_{EX}^{{(10)}}$ term, as seen for inhibitor 25 whose fragment is slightly too bulky to fit well in the C4 subpocket. Finally, we have shown that the $E_{ELMT}^{{(10)}} + E_{Das}^{{(10)}}$ model for the C7 subpocket could be transferred to the C4 subpocket with refitting of the $\beta$ constant term. The model could therefore be applied to the prediction of novel compounds capable of reversible binding to the target enzyme. The observed partial transferability and favorable computational scaling of the $E_{ELMT}^{{(10)}} + E_{Das}^{{(10)}}$ model opens possibilities for future applications in lead optimization. The most accurate inhibitory activity predictions can be expected for a set of compounds with similar solvation energy and the binding poses that share a common characteristics. The transferability of the $E_{ELMT}^{{(10)}} + E_{Das}^{{(10)}}$ model between different subpockets should be investigated further for larger sets of compounds with more diverse chemical properties.

Acknowledgements The project was financed in part by a statutory activity subsidy No. 0401/0259/16 from the Polish Ministry of Science and Higher Education for the Faculty of Chemistry at the Wrocław University of Technology and Heidelberg Institute for Theoretical Studies (HITS). We thank the BioNaM Project financed from the European Social Fund and Human Capital Operational Programme for the support. We gratefully acknowledge the support of the Klaus Tschira Foundation. This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under Grant Agreement No. 603240 (NMTrypI – New Medicine for Trypanosomatidic Infections, http://www.nmtrypi.eu/). JPH additionally acknowledges support from the Polish National Science Centre (grant no. 2016/21/D/NZ1/02806) and BIONMS program at the Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University. Calculations were performed at the Wrocław Supercomputer and Networking Center (WCSS) and Heidelberg Institute for Theoretical Studies (HITS).

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Leach AR, Shoichet BK, Peishoff CE (2006) Prediction of protein–ligand interactions. Docking and scoring: successes and gaps. J Med Chem 49:5851–5855
2. Doweyko AM (2004) 3D-QSAR illusions. J Comput Aided Mol Des 18:587–596
3. Yilmazer ND, Korth M (2013) Comparison of molecular mechanics, semi-empirical quantum mechanical, and density functional theory methods for scoring protein-ligand interactions. J Phys Chem B 117:8075–8084
4. Carlson HA, Smith RD, Damm-Ganamet KL, Stuckey JA, Ahmed A, Convery MA, Somers DO, Kranz M, Elkins PA, Cui G, Peishoff CE, Lambert MH, Dunbar JB Jr (2016) CSAR 2014: a benchmark exercise using unpublished data from pharma. J Chem Inf Model 6:1063–1077
5. Dyguda E, Grembecka J, Sokalski WA, Leszczyński J (2005) Origins of the activity of PAL and LAP enzyme inhibitors: towards ab initio binding affinity prediction. J Am Chem Soc 127:1658–1659
6. Grembecka J, Kędzierski P, Sokalski WA, Leszczyński J (2001) Electrostatic models of inhibitory activity. Int J Quantum Chem 83(3–4):180–192
7. Giedroyć-Piasecka W, Dyguda-Kazimierowicz E, Beker W, Mor M, Lodola A, Sokalski WA (2014) Physical nature of fatty acidamide hydrolase interactions with its inhibitors: testing a simple nonempirical scoring model. J Phys Chem B 118(51):14727–14736
8. Lonsdale R, Harvey JN, Mulholland AJ (2010) Inclusion of dispersion effects significantly improves accuracy of calculated reaction barriers for cytochrome P450 catalyzed reactions. J Phys Chem Lett 1:3232–3237
9. Cornell WD, Cieplak P, Bayly CI, Gould IM, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA (1995) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117:5179–5197
10. Kolář M, Berka J, Jurečka P, Hobza P (2010) On the reliability of the AMBER force field and its empirical dispersion contribution for the description of noncovalent complexes. ChemPhysChem 11:2399–2408
11. Zgarbová M, Otteype M, Šponer J, Hobza P, Jurečka P (2010) Large-scale compensation of errors in pairwise-additive empirical force fields: comparison of AMBER intermolecular terms with rigorous DFT-SAPT calculations. Phys Chem Chem Phys 12:10476–10493
12. Paton RS, Goodman JM (2009) Hydrogen bonding and pi-stacking: how reliable are force fields? A critical evaluation of force field descriptions of nonbonded interactions. J Chem Inf Model 49:944–955
13. Wieczorek R, Haskamp L, Dannenberg JJ (2004) Molecular orbital calculations of water clusters on counterpoise-corrected potential energy surfaces. J Phys Chem A 108:6713–6723
14. Wu Q, Yang WT (2002) Empirical correction to density functional theory for van der waals interactions. J Phys Chem A 106:515–524
15. Grimme S (2004) Accurate description of van der Waals complexes by density functional theory including empirical corrections. J Comput Chem 25:1463–1473
16. Korth M (2013) Error estimates for (semi-)empirical dispersion terms and large biomacromolecules. Org Biomol Chem 11:6515–6519
17. Pernal K, Podeszwa R, Patkowski K, Szalewicz K (2009) Dispersionless density functional theory. Phys Rev Lett 103(26):263201
18. Jezierski B, Moszyński R, Szalewicz K (1994) Perturbation theory approach to intermolecular potential energy surfaces of van der Waals complexes. Chem Rev 94(7):1887–1930
19. Podeszwa R, Pernal K, Patkowski K, Szalewicz K (2010) Extension of the Hartree–Fock plus dispersion method by first-order correlation effects. J Phys Chem Lett 1(2):550–555
20. Spinks D, Ong HB, Mpamhanga CP, Shanks EJ, Robinson DA, Collie IT, Read KD, Frearson JA, Wyatt PG, Brenk R, Fairlamb AH, Gilbert IH (2011) Design, synthesis and biological evaluation of novel inhibitors of Trypanosoma brucei pteridine reductase 1. ChemMedChem 6(2):302–308
21. Nare B, Hardy LW, Beverley SM (1997) The roles of pteridine reductase 1 and dihydrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major. J Biol Chem 272(21):13883–13891
22. Robello C, Navarro P, Castansy S, Gamarro F (1997) A pteridine reductase gene ptr1 contiguous to a P-glycoprotein confers resistance to antifolates in Trypanosoma cruzi. Mol Biochem Parasitol 90(2):525–535
23. Mpamhanga CP, Spinks D, Tulloch LB, Shanks EJ, Robinson DA, Collie IT, Fairlamb AH, Wyatt PG, Frearson JA, Hunter WN, Gilbert IH, Brenk R (2009) Three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening. J Med Chem 52(14):4454–4465
24. Cavazzuti A, Patglietti G, Hunter WN, Gamarro F, Piras S, Loriga M, Allecca S, Corona P, McLuskey K, Tulloch L, Gibellini F, Ferrari S, Costi MP (2008) Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proc Natl Acad Sci USA 105(5):1448–1453
25. Corona P, Gibellini F, Cavalli A, Saxena P, Carta A, Loriga M, Luciani R, Patglietti G, Guerrerdi D, Nerini E, Gupta S, Hanaaft V, Michels PAM, Ferrari S, Costi PM (2012) Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors. J Med Chem 55(19):8318–8329
26. Dawson A, Gibellini F, Sienkiewicz N, Tulloch LB, Fye PK, McLuskey K, Fairlamb AH, Hunter WN (2006) Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the acetylated antifolate methotrexate. Mol Microbiol 61(6):1457–1468
27. Sastry GM, Adzhigirey M, Day T, Annabhimouju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221–234
28. Schrödinger LLC, New York NY (2015) Schrödinger Suite 2015–2. Maestro version 10.2
29. Schrödinger LLC, New York, NY (2015) Schrödinger Suite 2015–2, Protein Preparation Wizard, Epik version 3.2, Impact version 6.7, Prime version 4.0
30. Banks J, Beard H, Cao Y, Cho A, Damm W, Farid R, Felts A, Schrödinger LLC, New York NY (2015) Schrödinger Suite 2015–2. Maestro version 10:2, Protein Preparation Wizard, Epik version 3.2, Impact version 6.7, Prime version 4.0
31. Li H, Robertson A, Jensen J (2005) Very fast empirical prediction and interpretation of protein pKa values. Proteins 55(19):8318–8329
32. Bas D, Rogers D, Jensen J (2008) Very fast prediction and rationalization of pKa values for protein-ligand complexes. Proteins 73:765–783
33. Olsson M, Sondergard C, Rostkowski M, Jensen J (2011) PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput 7:525–537
34. Sondergard C, Olsson M, Rostkowski M, Jensen J (2011) Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa values. J Chem Theory Comput 7:2284–2295
35. Freisner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for...
rapid, accurate docking and scoring. 1. method and assessment of docking accuracy. J Med Chem 47(7):1739–1749
36. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49(21):6177–6196
37. Gourley D, Leonard ASG, Luba J, Hardy L, Beverley S, Hunter W (2001) Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites. Nature Struct Biol 8(6):521–525
38. Sokalski WA, Roszak S, Pecul K (1988) An efficient procedure for decomposition of the scf interaction energy into components with reduced basis set dependence. Chem Phys Lett 153:153–159
39. Góra R, Sokalski WA, Leszczyński J, Pett V (2005) The nature of interactions in the ionic crystal of 3-pentenenitrile, 2-nitro-5-o xo, ion(-1) sodium. J Phys Chem B 109:2027–2033
40. Sokalski WA, Sawaryn A (1987) Correlated molecular and cumulative atomic multipole moments. J Chem Phys 87:526–534
41. Schmidt MW, Baldrige KK, Boatz JA, Elbert ST, Gordon MS, Jensen JH, Kosiski S, Matsunaga N, Nguyen KA, Su SJ, Windus TL, Dupuis M, Montgomery JA (1993) General atomic and molecular electronic structure system. J Comput Chem 14(11):1347–1363
42. Krishnan R, Binkley JS, Seeger R, Pople JA (1980) Selfconsistent molecular orbital methods. XX. A basis set for correlated wave functions. J Chem Phys 72(10):6539–6548
43. McLean AD, Chandler GS (1980) Contracted gaussian basis sets for molecular calculations. I. Second row atoms, Z=11–18. J Chem Phys 72(10):6539–6548
44. Wachters AH (1970) Gaussian basis set for molecular wavefunctions containing third-row atoms. J Chem Phys 52:1033–1036
45. Hay PJ (1977) Gaussian basis sets for molecular calculations—representation of 3D orbitals in transition-metal atoms. J Chem Phys 66:4377–4384
46. Boys S, Bernardi F (1970) The calculation of small molecular interactions by the differences of separate total energies. Some procedures with reduced errors. Mol Phys 19:553–566
47. Sokalski WA, Poirier RA (1983) Cumulative atomic multipole representation of the molecular charge distribution and its basis set dependence. Chem Phys Lett 98(1):86–92
48. Grimme S, Antony J, Ehrlich S, Krieg H (2010) A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. J Chem Phys 132(15):154104
49. Grimme S, Ehrlich S, Goerigk L (2011) Effect of the damping function in dispersion corrected density functional theory. J Comput Chem 32(7):1456–1465
50. Perdew JP, Burke K, Ernzerhof M (1996) Generalized gradient approximation made simple. Phys Rev Lett 77(18):3865–3868
51. Adamo C, Barone V (1999) Toward reliable density functional methods without adjustable parameters: the PBE0 model. J Chem Phys 110(13):6158–6170
52. Becke AD (1993) Density-functional thermochemistry. III. The role of exact exchange. J Chem Phys 98(7):5648–5652
53. Tao JM, Perdew JP, Staroverov VN, Scuseria GE (2003) Climbing the density functional ladder: nonempirical meta-generalized gradient approximation designed for molecules and solids. Phys Rev Lett 91(14):146401
54. Langner K, Beker W, Sokalski W (2012) Robust predictive power of the electrostatic term at shortened intermolecular distances. J Phys Chem Lett 3:2785–2789
55. Schrödinger LLC, New York NY (2015) Schrödinger Suite 2015–2. Glide version 6.7
56. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 11(5):425–445
57. Berg JM, Tymoczko JL, Stryer L (2012) Biochemistry, 7th edn. W.H. Freeman, Basingstoke
58. Grzywa R, Dyguda-Kazimierowicz E, Siewiczzyk M, Feliks M, Sokalski WA, Oleksyzyzn J (2007) The molecular basis of urokinase inhibition: from the nonempirical analysis of intermolecular interactions to the prediction of binding affinity. J Mol Model 13(6–7):677–683
59. Klebe G (2006) Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 11:580–594
60. Plewczyński D, Łaźniewski M, Augustyniak R, Ginalski K (2011) Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database. J Comput Chem 32:742–755
61. Wilcken R, Zimmermann MO, Lange A, Joerger AC, Boeckler FM (2013) Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J Med Chem 56(4):1363–1388

 Springer